Pablo Mozas, Romain Ould Ammar, Loïc Chartier, Loretta Nastoupil, Emmanuel Bachy, Silvia Maria Bezsera, Jeffrey Barnes, Fontanet Bijou, André Goy, Hacène Zerazhi, Guillaume Cartron, Mario Ojeda-Uribe, Sylvain Choquet, Bertrand Joly, Morgane Cheminant, Alejandro Martín García-Sancho, Herbert Eradat, Rémy Gressin, Pau Abrisqueta, Anne Parcelier, María José Rodríguez Salazar, Christophe Bonnet, Nathalie A Johnson, Armando López-Guillermo, Franck Morschhauser
{"title":"A low lymphocyte-to-monocyte ratio is independently associated with early relapse (POD24) in high tumour burden follicular lymphoma: A RELEVANCE subanalysis.","authors":"Pablo Mozas, Romain Ould Ammar, Loïc Chartier, Loretta Nastoupil, Emmanuel Bachy, Silvia Maria Bezsera, Jeffrey Barnes, Fontanet Bijou, André Goy, Hacène Zerazhi, Guillaume Cartron, Mario Ojeda-Uribe, Sylvain Choquet, Bertrand Joly, Morgane Cheminant, Alejandro Martín García-Sancho, Herbert Eradat, Rémy Gressin, Pau Abrisqueta, Anne Parcelier, María José Rodríguez Salazar, Christophe Bonnet, Nathalie A Johnson, Armando López-Guillermo, Franck Morschhauser","doi":"10.1111/bjh.20038","DOIUrl":"https://doi.org/10.1111/bjh.20038","url":null,"abstract":"<p><p>The peripheral blood lymphocyte-to-monocyte ratio (LMR) has been shown to predict outcomes in follicular lymphoma (FL). Among 1018 patients from the RELEVANCE trial (for previously untreated, high tumour burden FL), the median LMR was 2.5 (range, 0.3-93.5) and an LMR cut-off of 2 was mostly associated with survival end-points. Patients with an LMR ≤2 (n = 372; 37%) were older and had higher risk disease. An LMR ≤2 was associated with a shorter progression-free survival (PFS) (hazard ratio [HR] = 1.39, p = 0.002) and overall survival (OS) (HR = 1.44, p = 0.049). The association of the LMR with PFS was significant in the rituximab plus chemotherapy arm (p = 0.01) and inconclusive in the rituximab plus lenalidomide arm (p = 0.08). Within the three Follicular Lymphoma International Prognostic Index risk categories, the LMR retained its association with PFS only in the low-risk group (p = 0.03). An LMR ≤2 was also associated with a higher risk of progression of disease within 24 months of treatment initiation (univariable odds ratio (OR) = 1.84, p < 0.001; multivariable OR = 1.58, p = 0.02). In conclusion, the LMR is an easily accessible parameter informative of outcomes in FL patients in need of treatment, being especially helpful in otherwise low-risk patients. Whether the incorporation of immunomodulators such as lenalidomide will reduce its negative prognostic value needs to be further investigated.</p>","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143539697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Effectiveness of nirmatrelvir/ritonavir in hospitalized haematological malignancy patients with mild-to-moderate COVID-19: A retrospective study.","authors":"Hongbin Yu, Tian Chen, Jiawei Li, Xin Zhang, Yu Wu","doi":"10.1111/bjh.20039","DOIUrl":"https://doi.org/10.1111/bjh.20039","url":null,"abstract":"<p><p>Patients with haematological malignancies (HMs) are highly vulnerable to COVID-19 due to their immunocompromised status, which leads to prolonged viral clearance and severe outcomes. Nirmatrelvir/ritonavir has shown efficacy in reducing severity and mortality in high-risk COVID-19 outpatients, but its effectiveness in hospitalized HM patients remains unclear. We conducted a retrospective study to assess the effectiveness of nirmatrelvir/ritonavir on mortality and viral clearance in hospitalized HM patients with mild-to-moderate COVID-19 during China's first COVID-19 surge. Mortality rate and viral clearance time were the primary end-points. Cox proportional hazards models were used to detect factors associated with mortality and viral clearance. A total of 116 HM patients, with a median age of 47.2 years, hospitalized for a minimum of 5 days with mild-to-moderate COVID-19, were included in this study. There was no difference in the 90-day mortality rate between HM patients treated with nirmatrelvir/ritonavir within 5 days and those not treated (4.9% vs. 5.3%, p = 1.000). Nirmatrelvir/ritonavir use within 5 days reduced the time to viral clearance (hazard ratio [HR] = 1.59, 95% confidence interval [CI] 1.04-2.42). Nirmatrelvir/ritonavir use within 5 days in hospitalized HM patients with mild-to-moderate COVID-19 does not reduce mortality but accelerates viral clearance.</p>","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143539701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sara Mato, Lorenzo Carità, Ariadna Colmenero, Mara Andrés, Olga Balagué, Maitane Andión, Itziar Astigarraga, Verónica Celis, Carmen Mendoza, Pilar Guerra-García, Lorena Valero, Ana Galera, María Tallón, Melina Pol, Natalia Castrejón-de-Anta, Leonie Frauenfeld, Noelia Garcia, Elías Campo, Itziar Salaverria, Jaime Verdú-Amorós
{"title":"Comprehensive analysis of relapsed-refractory mature B-cell non-Hodgkin lymphoma in children and adolescents.","authors":"Sara Mato, Lorenzo Carità, Ariadna Colmenero, Mara Andrés, Olga Balagué, Maitane Andión, Itziar Astigarraga, Verónica Celis, Carmen Mendoza, Pilar Guerra-García, Lorena Valero, Ana Galera, María Tallón, Melina Pol, Natalia Castrejón-de-Anta, Leonie Frauenfeld, Noelia Garcia, Elías Campo, Itziar Salaverria, Jaime Verdú-Amorós","doi":"10.1111/bjh.20012","DOIUrl":"https://doi.org/10.1111/bjh.20012","url":null,"abstract":"<p><p>The outcome of B-cell non-Hodgkin lymphoma (B-NHL) in children and adolescents has improved significantly over recent decades due to risk-adapted strategies and the use of immunotherapy. However, refractory or relapsed (R/R) B-NHL remains extremely difficult to cure (<30%). This retrospective study of 45 patients with R/R B-NHL reflects the limited benefit associated with reintroducing rituximab in second-line strategies, the importance of achieving complete remission before stem cell transplantation and the potential role of TP53 as a biomarker in R/R B-NHL. TP53 mutations were identified in 44% of tumours and associated with a worse 3-year overall survival (15% vs. 80%; p = 0.048).</p>","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143514157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Laura Crisafulli, Margherita Correnti, Elena Gammella, Elisa De Camilli, Matteo Brindisi, Eleonora Palagano, Chiara Milanesi, Gabriele Todisco, Matteo G Della Porta, Cristina Sobacchi, Gaetano Cairo, Francesca Ficara, Stefania Recalcati
{"title":"Iron trapping in macrophages reshapes the homeostasis of the haematopoietic system.","authors":"Laura Crisafulli, Margherita Correnti, Elena Gammella, Elisa De Camilli, Matteo Brindisi, Eleonora Palagano, Chiara Milanesi, Gabriele Todisco, Matteo G Della Porta, Cristina Sobacchi, Gaetano Cairo, Francesca Ficara, Stefania Recalcati","doi":"10.1111/bjh.20031","DOIUrl":"https://doi.org/10.1111/bjh.20031","url":null,"abstract":"<p><p>Iron is required for key physiological processes, like oxygen transport, energy production and cell proliferation. Body iron homeostasis is regulated by the erythroferrone-hepcidin-ferroportin (FPN) axis, which mainly acts on absorptive duodenal cells and macrophages involved in iron recycling from red blood cell breakdown. In addition to systemic iron regulation, macrophages are also involved in local iron release to neighbouring cells. Similarly, bone marrow (BM)-resident macrophages could represent promptly available local sources of iron for developing haematopoietic cells. To study the impact of macrophage-released iron on BM haematopoietic stem and progenitor cells, we employed mice with targeted deletion of Fpn in the myeloid lineage (Fpn conditional knockout or Fpn-cKO). Fpn-cKO mice develop age-related anaemia and microcytaemia, reduction of BM erythroblasts and preferential megakaryopoiesis at the expenses of erythropoiesis, suggesting that red cells are mostly affected by the lack of myeloid-derived iron delivery. Transferrin receptor 1 surface expression is higher in Fpn-cKO mice than littermate controls in all the BM subpopulation analysed, starting from haematopoietic stem cells, indicating a broad BM sensitivity to lower iron availability. Last, Fpn-cKO mice activate systemic compensatory mechanisms, such as extramedullary haematopoiesis and erythroferrone upregulation, albeit not sufficient to overcome anaemia.</p>","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143514172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Lu Lu, Chenfei Liu, Lezong Chen, Xumiao Zhang, Yinglin Su, Zhenzhen Chou, Yang Liang, Yuanbin Song
{"title":"Understanding erythroid physiology and pathology in humanized mice: A closer look.","authors":"Lu Lu, Chenfei Liu, Lezong Chen, Xumiao Zhang, Yinglin Su, Zhenzhen Chou, Yang Liang, Yuanbin Song","doi":"10.1111/bjh.20023","DOIUrl":"https://doi.org/10.1111/bjh.20023","url":null,"abstract":"<p><p>Erythropoiesis, the process of red blood cell (RBC) development from haematopoietic stem cells, is crucial in haematology research due to its intricate regulation and implications in various pathologies such as anaemia and haemoglobinopathies. Humanized mice, created by introducing human cells or tissues into immunodeficient mice, offer a promising avenue in vivo approach. However, challenges persist in fully replicating human erythropoiesis in these models, particularly in generating mature human RBCs capable of sustained circulation. This review discusses the differences between human and mouse erythropoiesis, recent progress made using refined humanized mouse models for studying human erythropoiesis and erythropoietic disorders, the challenges that impede a faithful mimicking of human phenotypes in these mice and recommendations for future research improvements. Despite progress being made, enhancing the translational potential of humanized mouse models for human erythropoiesis research remains a priority.</p>","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143497472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Acute myeloid leukaemia with SRSF2 and BRAF mutations preceded by histiocytic proliferation in the bone marrow.","authors":"Minako Mori, Tomomi Sakai, Tomomi Oka, Maki Sakurada, Makoto Iwasaki, June Takeda, Junya Kanda, Yasuhito Nannya, Seishi Ogawa, Akifumi Takaori-Kondo, Koki Moriyoshi, Hiroshi Kawabata","doi":"10.1111/bjh.20028","DOIUrl":"https://doi.org/10.1111/bjh.20028","url":null,"abstract":"","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143497465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Outcomes and prognostic factors associated with relapse after haploidentical stem cell transplantation for paediatric T-cell acute lymphoblastic leukaemia.","authors":"Chen Zhao, Meng-Yu Xiao, Feng Zhang, Lu Bai, Guan-Hua Hu, Pan Suo, Feng-Rong Wang, Zhi-Dong Wang, Xiao-Dong Mo, Yu Wang, Yuan-Yuan Zhang, Lan-Ping Xu, Xiao-Jun Huang, Yi-Fei Cheng, Xiao-Hui Zhang","doi":"10.1111/bjh.20007","DOIUrl":"https://doi.org/10.1111/bjh.20007","url":null,"abstract":"<p><p>The outcomes are poor for paediatric patients with T-cell acute lymphoblastic leukaemia (T-ALL) who relapse after haematopoietic stem cell transplantation (HSCT). However, studies focusing on paediatric patients with T-ALL following haploidentical HSCT (haplo-HSCT) are limited. We retrospectively identified a consecutive cohort comprising of 128 paediatric T-ALL after haplo-HSCT from 2642 consecutive ALL patients between January 2010 and June 2022. The 2-year overall survival and leukaemia-free survival were 67.77% ± 4.21% and 66.34% ± 3.82%, respectively, and the cumulative incidence of relapse (CIR) and non-relapse mortality were 33.82% ± 0.70% and 12.65% ± 0.46% respectively. According to the multivariate Cox regression analysis, CD34 cells, minimal residual disease (MRD) ≥0.01% before HSCT, chronic graft-versus-host disease (cGvHD) and cytomegalovirus were associated with relapse (p < 0.05). To develop a scoring system for stratifying patients, we combined the variables and stratified them into low (0-2 points) and high (3, 4) groups. Consequently, the 2-year CIR in low and high groups were 23.76% ± 1.83% and 48.22% ± 2.42% (p = 0.009), respectively. Children with T-ALL have poor long-term survival, and haplo-HSCT is a potent and safe treatment; however, the incidence of relapse is high. Eliminating pre-HSCT MRD, guaranteeing sufficient CD34 cells infusion and the occurrence of cGvHD and cytomegalovirus reactivation may benefit from relapse.</p>","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143490223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Tianyu Sun, Shalini Singh, Hayson Chenyu Wang, Juseong Lee, Hamid Dolatshad, Pak Leng Cheong, Douglas R Higgs, Jacqueline Boultwood, Andrea Pellagatti
{"title":"Identification of new candidate drugs in myelodysplastic syndromes with splicing factor mutations by transcriptional profiling and connectivity map analysis.","authors":"Tianyu Sun, Shalini Singh, Hayson Chenyu Wang, Juseong Lee, Hamid Dolatshad, Pak Leng Cheong, Douglas R Higgs, Jacqueline Boultwood, Andrea Pellagatti","doi":"10.1111/bjh.20026","DOIUrl":"https://doi.org/10.1111/bjh.20026","url":null,"abstract":"<p><p>We sought to identify new candidate drugs for repurposing to myelodysplastic syndromes (MDS). Connectivity map analysis was performed on gene expression signatures generated from bone marrow CD34<sup>+</sup> cells of splicing factor mutant MDS patients. Celastrol and Withaferin A (WA), two top-ranking compounds identified, markedly inhibited proliferation, arrested the cell cycle and induced apoptosis in leukaemia cells. These compounds also inhibited the viability of primary bone marrow MDS cells. We showed that Celastrol and WA inhibit interleukin-1 receptor-associated kinase 4-mediated nuclear factor kappa-light-chain-enhancer of activated B cells signalling activation in splicing factor mutant MDS and leukaemia cells. Celastrol and WA may represent novel candidate drugs for the treatment of MDS.</p>","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143481804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"How I treat iron-refractory iron deficiency anaemia-An expert opinion-based treatment guidance for children and adults.","authors":"V Hoving, A E Donker, S E M Schols, D W Swinkels","doi":"10.1111/bjh.20030","DOIUrl":"https://doi.org/10.1111/bjh.20030","url":null,"abstract":"<p><p>Iron-refractory iron deficiency anaemia (IRIDA) is a rare hereditary microcytic anaemia characterized by partial or complete resistance to oral iron supplementation, caused by elevated plasma hepcidin levels resulting from pathogenic variants in the TMPRSS6 gene. Although intravenous iron supplementation is often effective, patient responses can vary significantly due to various factors, and potential side effects of this treatment remain unclear. Additionally, evidence-based international guidelines for diagnosing and managing IRIDA are lacking. This review aims to provide patient-tailored treatment strategies, informed by case studies and expert opinion, to address the specific therapeutic needs of both children and adults with IRIDA.</p>","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143476168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Elisabetta Metafuni, Filippo Achille Brioschi, Andrea Patriarca, Claudia Leoni, Giorgia Battipaglia, Daniela Carlino, Annalisa Condorelli, Valeria Di Giacomo, Sarah Marktel, Maria Antonietta Marzilli, Maurizio Miglino, Esther Natalie Oliva, Antonella Sau, Alessandra Ricco, Grazia Sanpaolo, Annarita Trolese, Anna Paola Iori, Simona Sica, Wilma Barcellini, Bruno Fattizzo
{"title":"Real-world evidence of pegcetacoplan in patients with paroxysmal nocturnal haemoglobinuria: A nationwide Italian study.","authors":"Elisabetta Metafuni, Filippo Achille Brioschi, Andrea Patriarca, Claudia Leoni, Giorgia Battipaglia, Daniela Carlino, Annalisa Condorelli, Valeria Di Giacomo, Sarah Marktel, Maria Antonietta Marzilli, Maurizio Miglino, Esther Natalie Oliva, Antonella Sau, Alessandra Ricco, Grazia Sanpaolo, Annarita Trolese, Anna Paola Iori, Simona Sica, Wilma Barcellini, Bruno Fattizzo","doi":"10.1111/bjh.20025","DOIUrl":"https://doi.org/10.1111/bjh.20025","url":null,"abstract":"<p><p>In this study, we collected real-world evidence on the use of pegcetacoplan among 22 Italian patients with paroxysmal nocturnal haemoglobinuria showing suboptimal response to anti-C5 treatments eculizumab and ravulizumab. Most patients exhibited a complete or good response as per the criteria of the European Bone Marrow Transplant group (Risitano et al. Front Immunol 2019) and median haemoglobin improvement from baseline was +3.6 g/dL. During the 6-month follow-up, 27% of patients displayed a breakthrough haemolytic event mainly managed with supportive treatment. No thromboses occurred.</p>","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143476169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
